PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2016, Vol 70, Issue
Abstract
Current cancer therapies are based mainly on the use of compounds that cause DNA damage. Unfortunately, even the combination therapies do not give rewarding effects, due to the high efficiency of DNA damage repair mechanisms in tumor cells. Therefore, the present studies should be focused on proteins that are involved in DNA repair systems. Poly(ADP-ribose) polymerase-1 is an example of a protein commonly known as an enzyme that plays a role in the detection of DNA damage and repair. Activation of PARP1 in response to DNA damage leads to poly-ADP-ribosylation of proteins contributing to DNA repair systems, therefore facilitating the maintenance of genome stability. On the other hand, inhibition of PARP1 enzyme results in the accumulation of DNA damage, which in turn contributes to cell death. Studies on inhibitors of PARP1 are still ongoing, and some of them are currently in the third phase of clinical trials. To date, only one representative of the PARP1 inhibitors, called olaparib, has been approved for anti-cancer therapy in the EU and the USA. Moreover, a growing body of evidence indicates a role of this protein in various intracellular processes such as bioenergetics, proliferation, regulation of gene expression, cell death as well as immunoregulation. A number of different intracellular processes regulated by PARP1 give rise to potential wider use of PARP1 inhibitors in treatment of other diseases, including immune or autoimmune disorders.
Authors and Affiliations
Ewelina Wiśnik, Marcin Ryksa, Maria Koter-Michalak
Keywords
Related Articles
- EP ID EP220760
- DOI -
- Views 151
- Downloads 0
The role of microbiological analysis as a diagnostic tool of periodontitis: a clinical study
Oral bacteria take the the form of biofilms, which – due to their complex structure – are characterized by high resistance to many external factors. The aim of the study was to analyze the composition of subgingival biof...
Zmienne fragmenty przeciwciał ciężkołańcuchowych (VHH): nowa magiczna kula medycyny?
Zwierzęta należące do rodziny Camelidae (wielbłądy i lamy) wytwarzają funkcjonalne przeciwciała pozbawione lekkich łańcuchów, nazywane przeciwciałami ciężkołańcuchowymi (hcAb). Zmienne regiony tych przeciwciał (VHH lub...
Leczenie zespołu nerczycowego: immuno- czy raczej podocytoterapia?
Zespół nerczycowy (ZN) jest to grupa objawów klinicznych będących skutkiem masywnego białkomoczu spowodowanego przez uszkodzenie bariery filtracyjnej kłębuszków nerkowych. Barierę tę stanowi błona podstawna naczyń kapila...
The efficiency of the bactericidal action of serum raised by complement and lysozyme against bacteria which avoid the immunological response of higher organisms
This paper presents some processes of the antibacterial effect of serum, which mainly results from the activities of complement (C) and lysozyme (muramidase, LZ). The C system consists of a group of serum proteins and ti...
Rola surwiwiny w diagnostyce i terapii nowotworów ginekologicznych
Surwiwina należy do rodziny inhibitorów apoptozy, oprócz hamowania programowanej śmierci komórek, pełni również ważną rolę w regulacji proliferacji, naprawie DNA oraz autofagii. Obecność surwiwiny wykryto w większości lu...